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Abstract
Recently, we reported that lysophosphatidic acid (LPA) induces long-lasting mechanical allodynia
and thermal hyperalgesia as well as demyelination and upregulation of pain-related proteins through
one of its cognate receptors, LPA1. In addition, mice lacking the LPA1 receptor gene (lpa1
-/- mice)
lost these nerve injury-induced neuropathic pain behaviors and phenomena. However, since lpa1
-/-
mice did not exhibit any effects on the basal nociceptive threshold, it is possible that nerve injury-
induced neuropathic pain and its machineries are initiated by LPA via defined biosynthetic pathways
that involve multiple enzymes. Here, we attempted to clarify the involvement of a single synthetic
enzyme of LPA known as autotaxin (ATX) in nerve injury-induced neuropathic pain. Wild-type
mice with partial sciatic nerve injury showed robust mechanical allodynia starting from day 3 after
the nerve injury and persisting for at least 14 days, along with thermal hyperalgesia. On the other
hand, heterozygous mutant mice for the autotaxin gene (atx+/-), which have 50% ATX protein and
50% lysophospholipase D activity compared with wild-type mice, showed approximately 50%
recovery of nerve injury-induced neuropathic pain. In addition, hypersensitization of myelinated
A-  o r  A δ-fiber function following nerve injury was observed in electrical stimuli-induced paw
withdrawal tests using a Neurometer®. The hyperalgesia was completely abolished in lpa1
-/- mice,
and reduced by 50% in atx+/- mice. Taken together, these findings suggest that LPA biosynthesis
through ATX is the source of LPA for LPA1 receptor-mediated neuropathic pain. Therefore,
targeted inhibition of ATX-mediated LPA biosynthesis as well as LPA1 receptor and its downstream
pathways may represent a novel way to prevent nerve injury-induced neuropathic pain.
Findings
Lysophosphatidic acid (LPA) is a representative lipid
mediator that has a variety of biological actions, including
roles in cell proliferation, migration and survival via its
cognate receptors LPA1/EDG2, LPA2/EDG4 and LPA3/
EDG7 [1-4]. Mice lacking LPA1 receptor do not develop
any signs of neuropathic pain, demyelination or upregu-
lation of pain-related gene/protein expression following
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nerve injury [5]. Nerve injury-induced neuropathic pain
and its underlying machineries are caused by a single
intrathecal (i.t.) injection of LPA, and blocked by knock-
down of LPA1 receptor at the early, but not late, stage.
These findings suggest that LPA1 receptor activation initi-
ates the machineries of neuropathic pain. Furthermore,
since deletion of the LPA1 receptor gene did not have any
effect on the basal nociceptive threshold, it is evident that
nerve injury-induced neuropathic pain and its machiner-
ies are initiated by LPA via defined biosynthetic pathways
that involve multiple enzymes [6,7]. Therefore, targeted
inhibition of LPA biosynthesis as well as LPA1 receptor
would be a valuable way to prevent nerve injury-induced
neuropathic pain. Autotaxin (ATX), which was originally
identified as a tumor cell motility factor, is known to have
lysophospholipase D (lysoPLD) activity and convert lyso-
phosphatidylcholine (LPC) to LPA [8,9]. Here, we report
the involvement of ATX in the development of partial sci-
atic nerve injury-induced neuropathic pain.
Male heterozygous mutant mice for the autotaxin  gene
(atx+/-) [10] and mutant mice for the lpa1 gene (lpa1
-/-)
[11], which were backcrossed with C57BL/6J mice at least
ten times before use, and their sibling wild-type mice
weighing 20–24 g from the same genetic background were
used. They were kept in a room maintained at 21 ± 2°C
with free access to a standard laboratory diet and tap
water. All procedures were approved by the Nagasaki Uni-
versity Animal Care Committee and complied with the
recommendations of the International Association for the
Study of Pain [12]. Partial ligation of the sciatic nerve of
the mice was performed under pentobarbital (50 mg/kg
i.p.) anesthesia, following the methods of Malmberg and
Basbaum [13]. In thermal paw withdrawal tests, nocicep-
tion was measured as the latency to paw withdrawal
evoked by exposure to a thermal stimulus [5,14]. Unanes-
thetized animals were placed in plexiglas cages on top of
a glass sheet and an adaptation period of 1 hour was
allowed. A thermal stimulator (IITC Inc., Woodland Hills,
CA, USA) was then positioned under the glass sheet and
the focus of the projection bulb was aimed exactly at the
middle of the plantar surface of a particular paw. Paw
pressure tests were performed as described previously
[5,15]. Mice were placed into a plexiglas chamber on a 6
× 6-mm wire mesh grid floor and allowed to acclimatize
for 1 hour. A mechanical stimulus was then delivered
onto the middle of the plantar surface of the right hind-
paw using a Transducer Indicator (Model 1601; IITC Inc.,
Woodland Hills, CA, USA). Electrodes (Neurotron Inc.,
Baltimore, MD) were attached to the right plantar surface
and instep of a particular paw, as previously described
[16]. Transcutaneous nerve stimuli with two sine-wave
pulses (250 and 2000 Hz) were applied using a Neurom-
eter CPT/C (Neurotron Inc. Blatimore, MD, USA). The
minimum intensity (µA) at which each mouse withdrew
its paw was defined as the current stimulus threshold.
Stimuli were applied at 10-minute intervals. Investigators
blinded to the phenotype of a gene carried out all experi-
ments. Statistical analyses were performed using Student's
t-test. Significance was set at p < 0.05.
In paw pressure tests, partial sciatic nerve injury in wild-
type (atx+/+) mice caused robust mechanical allodynia
starting from day 3 after the nerve injury and persisting
until at least day 14 (Figure 1A), consistent with a previ-
ous report [5]. There was no significant difference in the
basal thresholds between heterozygous (atx+/-) and wild-
type (atx+/+) mice. As shown in Figure 1A, the degree of
mechanical allodynia was less evident in atx+/- mice than
in atx+/+ mice. The threshold in atx+/- mice with injury was
between the level in sham-operated atx+/+ mice or atx+/-
mice and that in atx+/+ mice with injury, and the differ-
ences from these other groups were statistically significant
for at least 14 days. Similar results were observed when
nerve injury-induced thermal hyperalgesia was evaluated
(Figure 1B).
We previously developed a nociceptive test (EPW test) to
evaluate nociceptive paw-withdrawal behavior in
response to electrical stimuli with different frequencies in
a Neurometer®, an apparatus that selectively activates sen-
sory neurons by using sine-wave pulses of different fre-
quencies [16]. As shown in Figure 1C (left panel), the
threshold for paw withdrawal upon 2000-Hz electrical
stimulation, which is supposed to stimulate Aβ fibers, was
approximately 320 µA in wild-type lpa1 
+/+ mice. Partial
sciatic nerve injury in wild-type (lpa1
+/+) mice caused a sig-
nificant decrease in the withdrawal threshold to 2000 µA
at day 7, which persisted until day14 (Figure 1C, left
panel). Although there was no significant difference in the
basal thresholds between knockout mice (lpa1
-/- mice) and
wild-type mice, the hypersensitivity was completely abol-
ished at days 7 and 14 in lpa1
-/- mice. On the other hand,
the hypersensitivity to 2000-Hz electrical stimulation at
day 14 after the nerve injury was partially, but signifi-
cantly, attenuated in atx+/- mice, which showed no signifi-
cant change in the threshold without injury (Figure 1D,
left panel). Quite similar results were observed when the
withdrawal responses induced by 250-Hz electrical stimu-
lation, which is supposed to stimulate Aδ fibers, were eval-
uated in lpa1
-/- mice and atx+/- mice with and without nerve
injury (Figure 1C and 1D, right panels).
In the present study, we used atx+/- heterozygous mutant
mice, since atx-/- homozygous mutant mice were reported
to die at the early stage of embryogenesis [10]. Therefore,
these heterozygous mice are expected to have half the
level of ATX expression, and indeed they were reported to
show 50% lysoPLD activity relative to wild-type mice
[10]. This finding is consistent with the present study, inMolecular Pain 2008, 4:6 http://www.molecularpain.com/content/4/1/6
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Partial blockade of neuropathic pain in atx+/- mice Figure 1
Partial blockade of neuropathic pain in atx+/- mice. (A, B) Partial blockade of mechanical allodynia and hyperalgesia in 
atx+/- mice. Paw pressure tests (A) were carried out on days 3, 7 and 14 after the nerve injury, while thermal paw withdrawal 
tests (B) were carried out on day 14 after the nerve injury. (C, D) Complete and partial blockade of Aβ (2000 Hz)- and Aδ 
(250 Hz)-fiber stimulation-induced hypersensitivities in lpa1
-/- (C) and atx+/- (D) mice, respectively. Behavior experiments were 
carried out on days 7 and 14 (C) and day 14 (D) after the nerve injury. All data represent the mean ± SEM from 5–6 separate 
experiments. *p < 0.05 compared with sham-operated mice; #p < 0.05 compared with wild-type mice with nerve injury.Molecular Pain 2008, 4:6 http://www.molecularpain.com/content/4/1/6
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which atx+/- heterozygous mice showed partial attenua-
tion of nerve injury-induced neuropathic pain, as
observed for conventional mechanical allodynia and ther-
mal hyperalgesia (Figure 1A), which are mediated
through LPA1 receptor activation [5].
On the other hand, nerve injury is known to cause func-
tional changes in myelinated A-fibers, such as demyelina-
tion, and upregulation of Ca2+channel  α2δ-1 subunits
and sodium channels in medium/large neurons of the
dorsal root ganglion would underlie the molecular mech-
anisms for neuropathic pain. Previously, we demon-
strated that nerve injury causes hypersensitization of
myelinated Aβ- and Aδ-fiber functions in an electrical
stimuli-induced paw flexion (EPF) test, which is a modi-
fied EPW test [17]. Here, we found that hypersensitization
of myelinated Aβ- and Aδ-fiber functions following nerve
injury was observed in the EPW test, and mediated
through LPA1  receptor activation (Figure 1C). Conse-
quently, we carried out further tests to clarify the involve-
ment of ATX in Aβ- and Aδ-fiber hypersensitization. The
atx+/- heterozygous mice showed significant and partial
attenuation of these phenomena. It is well known that
LPA is mainly produced via two major pathways, namely
LPC conversion mediated by activation of ATX and phos-
phatidic acid conversion mediated by activation of phos-
pholipase A2 (PLA2) [6,7]. However, all the findings in the
present report suggest that nerve injury-induced LPA pro-
duction mainly occurs through LPC conversion mediated
by activation of ATX.
There are reports that LPC is produced under physiologi-
cal and pathological conditions [18,19]. Furthermore,
LPC treatment of the saphenous or sciatic nerve induced
neuropathic pain-like behaviors, such as mechanical allo-
dynia and thermal hyperalgesia, as well as demyelination
and upregulation of pain-related proteins in the dorsal
root ganglion [20]. More recently, we found that i.t. injec-
tion of LPC induces neuropathic pain-like behaviors
through ATX-LPA1 receptor signaling, since these behav-
iors were completely abolished in lpa1
-/-mice and partially
blocked in atx+/- heterozygous mutant mice [21]. There-
fore, LPC is involved in neuropathic pain.
We previously reported that i.t. injection of an antisense
oligonucleotide for LPA1 receptor or inhibitors of RhoA/
ROCK, one of the downstream signaling molecules of
LPA1 receptor, completely abolished nerve injury-induced
neuropathic pain [5]. Furthermore, i.t. injection of LPA
mimics nerve injury-induced neuropathic pain. Therefore,
nerve injury seems to cause LPA production in the spinal
cord. ATX protein is present in the cerebrospinal fluid
(CSF) and has lysoPLD activity to convert LPC into LPA
[22]. On the other hand, LPC is not present in CSF [22].
Therefore, nerve injury would produce LPC in the spinal
cord, which would subsequently be hydrolyzed by ATX to
form LPA. Experiments to evaluate LPA and LPC produc-
tion following nerve injury and clarify the relationship of
ATX to LPA production are the next important issues to be
addressed.
In addition to the lysoPLD activity to convert LPC to LPA,
ATX also possesses activity to convert sphingosylphospho-
rylcholine to bioactive sphingosine-1-phosphate [23].
However, we previously reported that i.t. injection of
sphingosine-1-phosphate did not cause neuropathic pain-
like allodynia or hyperalgesia [5]. These findings suggest
that the marked reduction of neuropathic pain in atx+/-
mice can be attributed to a reduction in LPA production
following nerve injury.
In summary, we have demonstrated that LPA biosynthesis
by ATX is the source of LPA for LPA1 receptor-mediated
neuropathic pain. Therefore, targeted inhibition of ATX-
mediated LPA biosynthesis as well as LPA1 receptor and its
downstream pathways may represent a novel way to pre-
vent nerve injury-induced neuropathic pain.
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